Gideon Sperling Loevinsohn, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Tract Infections | 4 | 2022 | 1013 | 1.750 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2022 | 149 | 1.320 |
Why?
|
| Viruses | 2 | 2022 | 373 | 1.160 |
Why?
|
| Chikungunya virus | 1 | 2024 | 56 | 0.920 |
Why?
|
| Zambia | 4 | 2022 | 273 | 0.720 |
Why?
|
| Picornaviridae Infections | 1 | 2021 | 97 | 0.690 |
Why?
|
| Circumcision, Male | 1 | 2021 | 149 | 0.690 |
Why?
|
| Influenza, Human | 2 | 2021 | 1540 | 0.690 |
Why?
|
| Hospitals, Rural | 1 | 2021 | 176 | 0.670 |
Why?
|
| Measles Vaccine | 1 | 2019 | 79 | 0.640 |
Why?
|
| Measles | 1 | 2019 | 181 | 0.570 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2021 | 365 | 0.540 |
Why?
|
| Disease Outbreaks | 1 | 2024 | 1763 | 0.490 |
Why?
|
| Virus Diseases | 1 | 2020 | 722 | 0.460 |
Why?
|
| Seroepidemiologic Studies | 4 | 2024 | 406 | 0.460 |
Why?
|
| Cross Infection | 1 | 2021 | 1425 | 0.400 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 3210 | 0.320 |
Why?
|
| Dominican Republic | 2 | 2024 | 79 | 0.300 |
Why?
|
| Health Personnel | 1 | 2021 | 3384 | 0.290 |
Why?
|
| HIV Infections | 4 | 2021 | 17492 | 0.260 |
Why?
|
| Leptospira | 1 | 2024 | 25 | 0.240 |
Why?
|
| Leptospirosis | 1 | 2024 | 45 | 0.230 |
Why?
|
| Explosive Agents | 1 | 2023 | 26 | 0.210 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 33 | 0.190 |
Why?
|
| Patients' Rooms | 1 | 2021 | 62 | 0.190 |
Why?
|
| Rhinovirus | 1 | 2021 | 210 | 0.170 |
Why?
|
| Uganda | 2 | 2021 | 1350 | 0.170 |
Why?
|
| Biodiversity | 1 | 2020 | 346 | 0.150 |
Why?
|
| Disaster Planning | 1 | 2023 | 560 | 0.140 |
Why?
|
| Circadian Clocks | 1 | 2017 | 168 | 0.120 |
Why?
|
| HIV | 1 | 2021 | 1587 | 0.110 |
Why?
|
| Infection Control | 1 | 2021 | 985 | 0.110 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 781 | 0.110 |
Why?
|
| Chest Pain | 1 | 2020 | 1099 | 0.110 |
Why?
|
| Ukraine | 2 | 2024 | 151 | 0.110 |
Why?
|
| Visual Pathways | 1 | 2017 | 559 | 0.100 |
Why?
|
| Epidemics | 1 | 2018 | 517 | 0.100 |
Why?
|
| Light | 1 | 2017 | 1357 | 0.090 |
Why?
|
| Retinal Ganglion Cells | 1 | 2017 | 811 | 0.090 |
Why?
|
| Infant | 3 | 2024 | 36496 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 1898 | 0.090 |
Why?
|
| Child | 4 | 2024 | 80856 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2024 | 42620 | 0.090 |
Why?
|
| Rural Population | 1 | 2020 | 2317 | 0.080 |
Why?
|
| Adult | 8 | 2024 | 223528 | 0.080 |
Why?
|
| Young Adult | 5 | 2024 | 60038 | 0.080 |
Why?
|
| Pneumonia | 1 | 2020 | 2162 | 0.080 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2010 | 229 | 0.080 |
Why?
|
| Humans | 15 | 2024 | 768369 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2021 | 41782 | 0.080 |
Why?
|
| Hepacivirus | 2 | 2018 | 1342 | 0.080 |
Why?
|
| Hepatitis C | 1 | 2018 | 1594 | 0.070 |
Why?
|
| Retina | 1 | 2017 | 2663 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3246 | 0.060 |
Why?
|
| Adolescent | 4 | 2024 | 89163 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 3412 | 0.060 |
Why?
|
| Endoplasmic Reticulum | 1 | 2010 | 1129 | 0.060 |
Why?
|
| Traumatology | 1 | 2024 | 101 | 0.060 |
Why?
|
| Female | 7 | 2024 | 396926 | 0.050 |
Why?
|
| Male | 7 | 2024 | 364761 | 0.050 |
Why?
|
| Russia | 1 | 2023 | 386 | 0.050 |
Why?
|
| Nucleocapsid | 1 | 2022 | 64 | 0.050 |
Why?
|
| Virus Replication | 1 | 2010 | 2443 | 0.050 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 7955 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 8751 | 0.050 |
Why?
|
| Hospitalization | 1 | 2020 | 10845 | 0.040 |
Why?
|
| Maryland | 1 | 2020 | 277 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2021 | 54913 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2024 | 1480 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2018 | 501 | 0.030 |
Why?
|
| Heart Failure | 1 | 2020 | 11859 | 0.030 |
Why?
|
| South Africa | 1 | 2021 | 1870 | 0.030 |
Why?
|
| Kinetics | 1 | 2022 | 6347 | 0.030 |
Why?
|
| Middle Aged | 4 | 2024 | 223406 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2018 | 530 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2022 | 2450 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2021 | 1343 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2024 | 2518 | 0.020 |
Why?
|
| Incidence | 2 | 2021 | 21552 | 0.020 |
Why?
|
| Curriculum | 1 | 2024 | 3778 | 0.020 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2010 | 31 | 0.020 |
Why?
|
| Transcription Factor CHOP | 1 | 2010 | 69 | 0.020 |
Why?
|
| Disease Management | 1 | 2020 | 2533 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2010 | 179 | 0.020 |
Why?
|
| Prevalence | 1 | 2024 | 15879 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 798 | 0.020 |
Why?
|
| Logistic Models | 1 | 2020 | 13323 | 0.020 |
Why?
|
| Risk Factors | 2 | 2024 | 74915 | 0.010 |
Why?
|
| Protein Transport | 1 | 2010 | 1964 | 0.010 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 2188 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14483 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 26348 | 0.010 |
Why?
|
| Aged | 2 | 2024 | 171514 | 0.010 |
Why?
|
| Animals | 2 | 2024 | 169424 | 0.010 |
Why?
|
| Base Sequence | 1 | 2010 | 12426 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8331 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 5803 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 17637 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 19035 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 81835 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 82051 | 0.010 |
Why?
|